+ Watch NEO
on My Watchlist
spec TP $5
This is a well run company, and is run by people that have started and developed other companies to the point they went public and were successful or were bought out. Just give it a little more time.
A new frontier for cancer diagnoses; should provide expanded information to physicians and patients.
This stock spam was originally sent to TMFBent:New York City – March 16, 2010 -- AMI Research, a leading provider of equity research reports and a division of IR Firm, Hawk Associates Inc., announced today that it has published updated stock research coverage on NeoGenomics, Inc. (OTCBB: NGNM) based on its fourth quarter 2009 financial earnings results. The AMI Research report provides an institutional-quality analysis of NeoGenomics’ fourth quarter providing key statistics, management, growth catalysts, financial outlook and valuation. The complete 11-page report is available for free download at the AMI Research website, http://www.amistockreports.com. About NeoGenomicsNeoGenomics Inc., (http://www.neogenomics.org) is a CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org. About AMI ResearchAMI Research is a wholly owned subsidiary of Hawk Associates and provides fundamental business analysis for promising companies that do not have traditional Wall Street analyst coverage. AMI Research creates comprehensive and quality equity research reports for small cap and microcap companies that need to reach investors. These detailed reports provide retail, individual and institutional investors with an in-depth understanding of a company's intrinsic value and its technology. The AMI equity research reports detail the company's industry, strategic position, core business model, financial history and future growth catalysts. AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst’s compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report. ****** Contact AMI Research:Peter D’Agostino, email@example.comHawk news on Facebook: http://www.facebook.com/hawkassociates News alerts on Twitter: http://www.twitter.com/stocksonhawk.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions